Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
September 12 2018 - 7:00AM
- Former CMO of Schering-Plough Joins
Cyclacel Board -
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP)
("Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer biology, announced
the appointment of Robert Spiegel, M.D., FACP, to its Board of
Directors.
"We are very pleased to have Dr. Robert Spiegel join the Board
of Directors of Cyclacel. His extensive research, clinical and
regulatory experience further adds to the strength of our Board and
will support management’s efforts to build shareholder value," said
David U'Prichard, Ph.D., Chairman of the Board of Cyclacel. "In
particular, Bob's experience in all development stages of cancer
medicines will be very valuable as we advance our business
strategy."
Dr. Spiegel has over 30 years of extensive R&D and
operational experience in biopharmaceuticals, including large
pharmaceutical and biotechnology companies, and academic startups
as well as an advisor to venture capital and private equity funds.
Dr. Spiegel was an Assistant Professor and Director of the
Developmental Therapeutics Program at New York University Medical
Center and then spent 25 years at Schering-Plough (subsequently
acquired by Merck & Co.), where he joined as the first Director
for Oncology Clinical Research. He subsequently held a series of
senior executive positions, including Senior Vice President for
Worldwide Clinical Research and Chief Medical Officer. During his
time at Schering-Plough he led teams that took numerous drug
candidates through clinical development and was involved with over
30 New Drug Application approvals by the U.S. FDA. For the last
seven years, he has been a consultant to the biotech industry and
has served on the Scientific Advisory Board and Board of Directors
of multiple biotech companies.
"We welcome Dr. Robert Spiegel, a highly regarded figure in our
industry, to our Board as an independent director," said Spiro
Rombotis, President and Chief Executive Officer of Cyclacel. "In
addition to his long experience in drug development and regulatory
affairs, Bob adds wide business expertise to our Board. We look
forward to working with him in advancing the development of
Cyclacel's pipeline."
"I am excited to join Cyclacel's Board of Directors at an
important moment in the Company's history," said Robert J. Spiegel,
M.D. "Cyclacel's pipeline includes multiple oncology programs
around the Company's kinase inhibitor portfolio, including CDK
inhibitors, a class with rising visibility in the pharmaceutical
industry."
Dr. Spiegel currently serves on the Board of Directors of Geron
Corporation and Edge Therapeutics, Inc. He is Chairman of Vidac
Pharma and former Executive Chairman of NexImmune, Inc. He is
currently the president of Spiegel Consulting LLC and an Assistant
Professor of Medicine at Weill Cornell Medical College. He is
also a Senior Advisor to the private equity firm Warburg Pincus and
an Advisor to the Israel Biotech Fund.
He received his B.A. from Yale University and his M.D. from the
University of Pennsylvania. He completed his specialty training at
the National Cancer Institute, National Institutes of Health
(NIH).
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical
company using cell cycle, transcriptional regulation and DNA damage
response biology to develop innovative medicines based on cancer
biology. Cyclacel's transcriptional regulation program is
evaluating CYC065, a CDK inhibitor, in patients with advanced
cancers. The DNA damage response program is evaluating a sequential
regimen of sapacitabine and seliciclib, a CDK inhibitor, in
patients with BRCA positive, advanced solid cancers. Cyclacel's
strategy is to build a diversified biopharmaceutical business
focused in hematology and oncology based on a pipeline of novel
drug candidates. For additional information, please visit
www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended
utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later
clinical trials, trials may have difficulty enrolling, Cyclacel may
not obtain approval to market its product candidates, the risks
associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsCompany:
Paul
McBarron, (908) 517-7330, pmcbarron@cyclacel.comInvestor
Relations:
Russo partners LLC, Alexander Fudukidis, (646) 942-5632,
alex.fudukidis@russopartnersllc.com
© Copyright 2018 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Sep 2023 to Sep 2024